Form 4: Gilead Sciences Increases Stake in Arcus Biosciences with $11 Purchase

Gilead Sciences, Inc. reports acquiring 1,363,636 shares of Arcus Biosciences, Inc. at $11 per share, increasing its holdings to 31,424,760 shares.

Summary

• Gilead Sciences, Inc. filed a Form 4 with the SEC on February 20, 2025.
• The filing reports a transaction that occurred on February 18, 2025.
• Gilead Sciences acquired 1,363,636 shares of Arcus Biosciences, Inc. (RCUS) common stock at a price of $11 per share.
• Following the transaction, Gilead Sciences beneficially owns 31,424,760 shares of Arcus Biosciences, Inc.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a factual report of a transaction. The increase in stake could be viewed positively, but the document itself is simply a disclosure.

Positives

• Gilead Sciences' increased investment in Arcus Biosciences could signal confidence in the company's future prospects.

Risks

• The Form 4 filing itself doesn't inherently indicate risks, but market conditions and Arcus Biosciences' performance could impact the value of Gilead's investment.

Industry Context

This transaction reflects ongoing investment activity in the biotechnology sector, where companies like Gilead Sciences often take strategic stakes in promising firms like Arcus Biosciences.

Stakeholder Impact

• Shareholders of Arcus Biosciences may react to the increased stake by Gilead Sciences.
• The transaction could influence investor confidence in Arcus Biosciences.

Key Dates

Keywords

Gilead Sciences, Arcus Biosciences, RCUS, Form 4, SEC, Beneficial Ownership, Investment, Shares